Expertise in
6
conditions

Naoyuki Nogami

JP 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
6
conditions
JP 

Overview

Naoyuki Nogami practices in Japan. Nogami is highly rated in 6 conditions, according to our data. Their top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Small Cell Lung Cancer (SCLC), and Tissue Biopsy.

Their clinical research consists of co-authoring 82 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Japan
Other Locations
Toon, Japan
Matsuyama, Japan
Minami, 8111395, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: April 03, 2026
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3
View 1 Less Clinical Trial

82 Total Publications

Impact of immunotherapy on survival and treatment patterns of patients with extensive-stage small cell lung cancer: a study using a Japanese nationwide database.
Impact of immunotherapy on survival and treatment patterns of patients with extensive-stage small cell lung cancer: a study using a Japanese nationwide database.
Journal: Future oncology (London, England)
Published: January 30, 2026

Frequently Asked Questions about Naoyuki Nogami

Is Naoyuki Nogami a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Naoyuki Nogami is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Naoyuki Nogami participate in research or clinical trials?

Yes. Naoyuki Nogami has published 82 articles and abstracts on conditions like Lung Cancer. You can view a list of Naoyuki Nogami's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Nogami's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile